Regorafenib in the treatment of malignant tumor / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 191-192,231, 2013.
Artículo
en Chino
| WPRIM
| ID: wpr-598211
ABSTRACT
Regorafenib,an oral multi-kinase inhibitor,can inhabit a class of receptor tyrosine kinase,such as angiogenic,stromal,oncogenic and so on.Studies in vitro and clinical trials indicate that Regorafenib has significant antitumor activity.The results of clinical trials are encouraging for the treatment of Refractory solid tumors,especially for colorectal carcinoma.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS